MYGN
Price
$3.89
Change
-$0.14 (-3.47%)
Updated
May 9 closing price
Capitalization
1.93B
82 days until earnings call
PROF
Price
$4.63
Change
-$0.35 (-7.03%)
Updated
May 9 closing price
Capitalization
205.33M
89 days until earnings call
Ad is loading...

MYGN vs PROF

Header iconMYGN vs PROF Comparison
Open Charts MYGN vs PROFBanner chart's image
Myriad Genetics
Price$3.89
Change-$0.14 (-3.47%)
Volume$3.87M
Capitalization1.93B
Profound Medical
Price$4.63
Change-$0.35 (-7.03%)
Volume$154.53K
Capitalization205.33M
MYGN vs PROF Comparison Chart
Loading...
MYGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PROF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MYGN vs. PROF commentary
May 10, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MYGN is a Hold and PROF is a Hold.

Ad is loading...
COMPARISON
Comparison
May 10, 2025
Stock price -- (MYGN: $3.89 vs. PROF: $4.63)
Brand notoriety: MYGN and PROF are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: MYGN: 211% vs. PROF: 189%
Market capitalization -- MYGN: $1.93B vs. PROF: $205.33M
MYGN [@Medical Specialties] is valued at $1.93B. PROF’s [@Medical Specialties] market capitalization is $205.33M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.43B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MYGN’s FA Score shows that 1 FA rating(s) are green whilePROF’s FA Score has 0 green FA rating(s).

  • MYGN’s FA Score: 1 green, 4 red.
  • PROF’s FA Score: 0 green, 5 red.
According to our system of comparison, PROF is a better buy in the long-term than MYGN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MYGN’s TA Score shows that 4 TA indicator(s) are bullish while PROF’s TA Score has 3 bullish TA indicator(s).

  • MYGN’s TA Score: 4 bullish, 4 bearish.
  • PROF’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, MYGN is a better buy in the short-term than PROF.

Price Growth

MYGN (@Medical Specialties) experienced а -48.54% price change this week, while PROF (@Medical Specialties) price change was -11.47% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -1.49%. For the same industry, the average monthly price growth was +3.17%, and the average quarterly price growth was -3.96%.

Reported Earning Dates

MYGN is expected to report earnings on Jul 31, 2025.

PROF is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Medical Specialties (-1.49% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MYGN($1.93B) has a higher market cap than PROF($205M). PROF YTD gains are higher at: -38.349 vs. MYGN (-71.627). PROF has higher annual earnings (EBITDA): -26.78M vs. MYGN (-197.4M). MYGN has more cash in the bank: 141M vs. PROF (26.2M). PROF has less debt than MYGN: PROF (7.94M) vs MYGN (152M). MYGN has higher revenues than PROF: MYGN (753M) vs PROF (7.2M).
MYGNPROFMYGN / PROF
Capitalization1.93B205M940%
EBITDA-197.4M-26.78M737%
Gain YTD-71.627-38.349187%
P/E RatioN/AN/A-
Revenue753M7.2M10,460%
Total Cash141M26.2M538%
Total Debt152M7.94M1,914%
FUNDAMENTALS RATINGS
MYGN vs PROF: Fundamental Ratings
MYGN
PROF
OUTLOOK RATING
1..100
39
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
38
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9193
PRICE GROWTH RATING
1..100
9763
P/E GROWTH RATING
1..100
2100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PROF's Valuation (38) in the null industry is somewhat better than the same rating for MYGN (97) in the Biotechnology industry. This means that PROF’s stock grew somewhat faster than MYGN’s over the last 12 months.

PROF's Profit vs Risk Rating (100) in the null industry is in the same range as MYGN (100) in the Biotechnology industry. This means that PROF’s stock grew similarly to MYGN’s over the last 12 months.

MYGN's SMR Rating (91) in the Biotechnology industry is in the same range as PROF (93) in the null industry. This means that MYGN’s stock grew similarly to PROF’s over the last 12 months.

PROF's Price Growth Rating (63) in the null industry is somewhat better than the same rating for MYGN (97) in the Biotechnology industry. This means that PROF’s stock grew somewhat faster than MYGN’s over the last 12 months.

MYGN's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for PROF (100) in the null industry. This means that MYGN’s stock grew significantly faster than PROF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MYGNPROF
RSI
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
71%
Bearish Trend 2 days ago
86%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
84%
MACD
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
77%
Advances
ODDS (%)
Bullish Trend 6 days ago
74%
Bullish Trend 6 days ago
74%
Declines
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 4 days ago
82%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
87%
Aroon
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
86%
View a ticker or compare two or three
Ad is loading...
MYGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PROF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PCBAX14.870.03
+0.20%
BlackRock Tactical Opportunities Inv A
MDDLX9.75N/A
N/A
MassMutual Diversified Value Adm
JSVDX14.06N/A
N/A
Janus Henderson Small-Mid Cap Value D
COSNX11.22N/A
N/A
Columbia Overseas Core Institutional
RNGGX60.26-0.07
-0.12%
American Funds New Economy R6

MYGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, MYGN has been loosely correlated with WAT. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if MYGN jumps, then WAT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MYGN
1D Price
Change %
MYGN100%
-3.47%
WAT - MYGN
39%
Loosely correlated
-1.94%
TMO - MYGN
35%
Loosely correlated
-1.86%
ATEC - MYGN
34%
Loosely correlated
-4.16%
GMED - MYGN
32%
Poorly correlated
-22.96%
ICUI - MYGN
31%
Poorly correlated
-3.20%
More

PROF and

Correlation & Price change

A.I.dvisor tells us that PROF and DHR have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PROF and DHR's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PROF
1D Price
Change %
PROF100%
-7.03%
DHR - PROF
30%
Poorly correlated
-2.61%
LZAGY - PROF
29%
Poorly correlated
+2.01%
TWST - PROF
28%
Poorly correlated
-5.49%
A - PROF
26%
Poorly correlated
-1.63%
MYGN - PROF
26%
Poorly correlated
-3.47%
More